RUA Life Sciences has provided a trading update for the 12-months to March 2023, ahead of publication of FY23 results, mid-July 2023. The company notes sales and profitability growth from its mature businesses and progress from its Vascular and Structural Heart businesses. RUA has managed cash resources, closing the year with £1.5m versus £3.0m at the close of FY22A. Importantly, the company has reached an agreement with the FDA regarding the regulatory process for the RUA vascular graft, includ ....
